Clinical experience of three pediatric and one adult case of spike-and-wave status epilepticus treated with injectable valproic acid.
Subclinical or nonconvulsive status epilepticus may cause severe postmorbid neurologic dysfunction. It is, therefore, critical to rapidly identify and treat these cases. The recent availability of injectable valproic acid (Depacon) provides an additional method for treatment of status epilepticus, although studies concerning its effectiveness are not widely available in the literature. We report four cases (three pediatric, one adult) of patients who presented to us in status epilepticus. All had previously failed more than one other common method of treatment for this condition. Treatment with injectable valproic acid resulted in the elimination of all clinical indications of status epilepticus as well as a return to the baseline EEG condition in all four cases. Seizure types included focal, multifocal, and generalized spike and wave forms, suggesting potential benefit from injectable valproic acid treatment in a wide range of status epilepticus patients. We present these cases for review.
Chez
M G
MG
Pediatric Epilepsy Program, Lake Forest Hospital, IL 60045, USA. mchezmd@internetaccess.com
Hammer
M S
MS
Loeffel
M
M
Nowinski
C
C
Bagan
B T
BT
D000328:Adult; D002648:Child; D004569:Electroencephalography / Q000187:drug effects; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D013226:Status Epilepticus / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome; D014635:Valproic Acid / Q000008:administration & dosage*
D014635:Valproic Acid